标题
Not too little, not too much—just right! (Better ways to give high dose melphalan)
作者
关键词
-
出版物
BONE MARROW TRANSPLANTATION
Volume 49, Issue 12, Pages 1457-1465
出版商
Springer Nature
发表日期
2014-08-18
DOI
10.1038/bmt.2014.186
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee
- (2014) Joseph Bubalo et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma
- (2014) S R Parmar et al. BONE MARROW TRANSPLANTATION
- Pancytopenia following vivax malaria in a CLL patient
- (2013) P. Sharma et al. BLOOD
- Cellular immunotherapy for plasma cell myeloma
- (2013) A L Garfall et al. BONE MARROW TRANSPLANTATION
- Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy
- (2013) Jonathan L. Kaufman et al. Clinical Lymphoma Myeloma & Leukemia
- Current treatments for renal failure due to multiple myeloma
- (2013) Efstathios Kastritis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
- (2013) Susan G Kreissman et al. LANCET ONCOLOGY
- Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
- (2013) D. Reece et al. ONCOLOGIST
- Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
- (2013) Mirta Kozelj et al. Radiology and Oncology
- Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan Hcl for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
- (2012) O.S. Aljitawi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Higher Melphalan Exposure Is Associated with Improved Overall Survival for Myeloma Patients Undergoing Autologous Transplant
- (2012) P.J. Shaw et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function
- (2012) Muneer H. Abidi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
- (2012) Ulas D. Bayraktar et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
- (2012) Margarita Blanes et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
- (2012) Taiga Nishihori et al. BRITISH JOURNAL OF HAEMATOLOGY
- Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma
- (2012) Rakesh Popat et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
- (2011) Dan T. Vogl et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
- (2011) M. T. Cibeira et al. BLOOD
- New developments in conditioning regimens before auto-SCT in multiple myeloma
- (2011) P Moreau et al. BONE MARROW TRANSPLANTATION
- Monoclonal antibodies in the treatment of multiple myeloma
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
- (2011) Manish Sharma et al. CANCER
- Genetic variations in multiple myeloma II: association with effect of treatment
- (2011) Annette Vangsted et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Liquid chromatography–tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma
- (2011) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
- (2010) Angela Dispenzieri et al. AMERICAN JOURNAL OF HEMATOLOGY
- Actual Weight To Calculate Surface Area Provides The Best Estimate Of AUC For Melphalan In Myeloma
- (2010) P.J. Shaw et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
- (2010) Christa E. Nath et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
- (2010) S. Lonial et al. CLINICAL CANCER RESEARCH
- Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
- (2010) J. J. Lahuerta et al. HAEMATOLOGICA
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
- (2009) A. Palumbo et al. BLOOD
- Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034): Table 1
- (2009) H. Miles Prince et al. BLOOD
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
- (2009) M. Roussel et al. BLOOD
- Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
- (2009) C Dumontet et al. BONE MARROW TRANSPLANTATION
- Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction
- (2009) M Rosenzweig et al. BONE MARROW TRANSPLANTATION
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
- (2009) Richard A. Campbell et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
- (2009) Katherine K. Matthay et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Plasma-Immune Cytokines throughout the High-Dose Melphalan-Induced Lymphodepletion in Patients with Multiple Myeloma: A Window for Adoptive Immunotherapy
- (2009) M. Condomines et al. JOURNAL OF IMMUNOLOGY
- An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma
- (2008) C. Nath Nath et al. ACTA CHROMATOGRAPHICA
- Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
- (2008) Muzaffar H. Qazilbash et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures
- (2008) R Ladenstein et al. BONE MARROW TRANSPLANTATION
- Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma
- (2008) Luciano J. Costa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Therapeutic Drug Monitoring of Busulfan in Transplantation
- (2008) J. Russell et al. CURRENT PHARMACEUTICAL DESIGN
- Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
- (2008) Samo Zver et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later
- (2008) Hillard M. Lazarus et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now